# A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes

> **NCT06471530** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immunwork, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** TE-8105 SAD Cohort 1
- **DRUG:** TE-8105 SAD Cohort 3
- **DRUG:** TE-8105 SAD Cohort 5 (Adaptive cohort)
- **DRUG:** TE-8105 MAD Cohort 1
- **DRUG:** TE-8105 MAD Cohort 2
- **DRUG:** TE-8105 SAD Cohort 2
- **DRUG:** TE-8105 SAD Cohort 4

## Key facts

- **NCT ID:** NCT06471530
- **Lead sponsor:** Immunwork, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-09
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-06-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06471530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06471530, "A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06471530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*